Assessing the cumulative effects of disease-modifying therapies on the current risk of irreversible disability in patients with relapsing-remitting multiple sclerosis
F. Rollot
,
Romain Casey
,
Marc Debouverie
,
Gilles Edan
,
S. Wiertlewski
et al.
Multiple Sclerosis Journal , 2018, 24, pp.344-345
Journal articles
hal-01935071v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Immunization and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
C. Lebrun
,
S. Vukusic
,
V. Abadie
,
C. Achour
,
F. Ader
et al.
Journal articles
hal-02546158v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Understanding heterogeneity in comparative effectiveness studies of natalizumab and fingolimod in multiple sclerosis: effect of analytical methodology
M. Lefort
,
S. Shannin
,
Jørgen Vitting Andersen
,
S. Vukusic
,
N. J. Koch-Henriksen
et al.
European Journal of Neurology , 2020, 27, pp.342-342
Journal articles
hal-02887182v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis
M. Lefort
,
S. Sharmin
,
J. Andersen
,
S. Vukusic
,
R. Casey
et al.
Journal articles
hal-03690493v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Comparative efficacyof fingolimod versus natalizumab in multiple sclerosis: a prospective multicenter observational study
D. A. Laplaud
,
L. Barbin
,
Chloé Rousseau
,
N. Jousset
,
Romain Casey
et al.
Multiple Sclerosis Journal , 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.62--63
Journal articles
hal-01259392v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Excess mortality in patients with relapsing-onset multiple sclerosis depends on age rather than disease duration: new insights from an innovative flexible model applied on French OFSEP data ('Observatoire Francais de la Sclerose en Plaques')
F. Rollot
,
M. Fauvernier
,
Z. Uhry
,
S. Vukusic
,
N. Bossard
et al.
Multiple Sclerosis Journal , 2019, 25, pp.103-104
Journal articles
hal-02363491v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Disease-modifying therapies use in primary progressive multiple sclerosis patients in France data from the OFSEP cohort over the 1996-2017 period
Emmanuelle Leray
,
F. Rollot
,
Romain Casey
,
J. de Seze
,
D. A. Laplaud
et al.
Journal articles
hal-01716028v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
High and low efficacy therapy in secondary progressive multiple sclerosis after accounting for therapeutic lag
I. Roos
,
Emmanuelle Leray
,
Romain Casey
,
D. Horakova
,
E. Kubala Havrdova
et al.
Multiple Sclerosis Journal , 2020, 26 (3_SUPPL), pp.534-535
Journal articles
hal-03127244v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Urinary tract infections and multiple sclerosis: Recommendations from the French Multiple Sclerosis Society
C. Donzé
,
C. Papeix
,
C. Lebrun-Frenay
,
N. Collongues
,
M. de Seze
et al.
Journal articles
hal-03339824v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Disease-modifying therapies use in relapsing-onset multiple sclerosis patients in real-life settings in France data from the OFSEP database over the period 1996-2017
Emmanuelle Leray
,
F. Rollot
,
Romain Casey
,
J. de Seze
,
D. A. Laplaud
et al.
Journal articles
hal-01716027v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Clinical course and therapeutic management of spms in france: a retrospective real world multicentric observational study (odyssep study)
Emmanuelle Leray
,
A. Bastien
,
K. Rerat
,
A. Cognee-Chauvin
,
E. Raponi
et al.
Multiple Sclerosis Journal , 2020, 26 (3_SUPPL), pp.524-525
Journal articles
hal-03105858v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Quelle utilisation des traitements de fond chez des patients ayant une sclérose en plaques rémittente en France sur la période 1990–2017 ? Étude des données de l’Observatoire français de la SEP
Emmanuelle Leray
,
Jonathan Roux
,
F. Rollot
,
Romain Casey
,
J. de Seze
et al.
Journal articles
hal-02921604v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Baseline characteristics of the first patients included in the OFSEP high definition cohort and relationship between quality of life and patients' characteristics
Romain Casey
,
I. El-Bahi
,
F. Rollot
,
Francis Guillemin
,
D. -A. Laplaud
et al.
Journal articles
hal-02363488v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
The OFSEP high definition cohort to prognosticate the evolution of multiple sclerosis at clinical key steps of the disease
Romain Casey
,
Francis Guillemin
,
D. A. Laplaud
,
Emmanuelle Leray
,
J. Epstein
et al.
Journal articles
hal-01939727v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Improving the decision to switch from first to second-line therapy in MS: a dynamic scoring system
C. Sabathe
,
Romain Casey
,
S. Vukusic
,
Emmanuelle Leray
,
G. Mathey
et al.
Journal articles
hal-03464227v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
MD1003 (high doses of biotin) in progressive multiple sclerosis: subgroup analyses of the MS-SPI trial
Ayman Tourbah
,
Christine Lebrun-Frenay
,
Gilles Edan
,
M. Clanet
,
C. Papex
et al.
Multiple Sclerosis Journal , 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.785
Journal articles
hal-01259396v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS
Caroline Lavie
,
Fabien Rollot
,
Françoise Durand-Dubief
,
Romain Marignier
,
Iuliana Ionescu
et al.
Journal articles
hal-02158735v1
Actions
Share
Gmail
Facebook
Twitter
LinkedIn
More